Mark Iwicki named CEO of DSP's Sunovion
This article was originally published in Scrip
Sunovion Pharmaceuticals, a Dainippon Sumitomo Pharma subsidiary that develops treatments for respiratory conditions and CNS disorders, has appointed its former chief operating officer, Mark Iwicki, president and chief executive officer. Mr Iwicki has been at Sunovion since October 2007, and previously served at companies such as Novartis, Merck and Astra Merck.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.